ALEC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 137880 min ago

@ $6.07

Išleistas: 13 vas. 2024 @ 22:46

Grąža: -10.38%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: -2.10 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	529 526
Vidutinė apimtis	600 068
Rinkos kapitalizacija	524.33M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-0.500 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	500 000	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Buy	98 533	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	98 533	Common Stock
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)

INSIDER POWER
-25.53
Last 100 transactions
Buy: 2 784 515 \| Sell: 4 159 752

Tūris Koreliacija

Ilgas: 0.25 (neutral)

Trumpas: 0.71 (moderate)

Signal:(73.417) Neutral

Alector Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AEHR	0.894
NEOG	0.893
VMAR	0.891
BROG	0.89
EHTH	0.889
LCID	0.885
EVOK	0.876
RVNC	0.876
NDRA	0.874
TXG	0.871

10 Labiausiai neigiamai susiję koreliacijos
BSCO	-0.847
ESTA	-0.83
NESR	-0.823
OXSQ	-0.82
PTMN	-0.817
LPCN	-0.811
SFBC	-0.81
KRUS	-0.808
IMPP	-0.805
AEAE	-0.802

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alector Inc Koreliacija - Valiuta/Žaliavos

-0.23
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.00
( neutral )

0.52
( weak )

Alector Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$97.06M
Bruto pelnas:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2023
Pajamos:	$97.06M
Bruto pelnas:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2022
Pajamos:	$133.62M
Bruto pelnas:	$125.15M (93.66 %)
EPS:	$-1.620

FY	2021
Pajamos:	$207.09M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.467

Financial Reports:

No articles found.

Alector Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.